Scribe Therapeutics, Inc. SCTX
Scribe Therapeutics, Inc. (Nasdaq: SCTX) is a cardio-renal-metabolic drug developer. Its lead program, STX-1150, is in Phase 1 for elevated LDL-C and increased risk of ASCVD.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| STX-1150 | elevated LDL-C and increased risk of ASCVD | gene therapy | Phase 1 |
| STX-1200 | genetically elevated Lp(a) and associated cardiovascular risk | gene therapy | Pre-clinical |
| STX-1400 | familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome, and severe hypertriglyceridemia | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.